메뉴 건너뛰기




Volumn 25, Issue 19, 2007, Pages 2642-2643

Shortening the infusion time of anticancer drugs: Who will benefit?

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CREMOPHOR; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; RITUXIMAB;

EID: 34447570856     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.7334     Document Type: Editorial
Times cited : (2)

References (11)
  • 1
    • 34447569438 scopus 로고    scopus 로고
    • Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    • Reidy DL, Chung KY, Timoney JP, et al: Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25:2691-2695, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 2691-2695
    • Reidy, D.L.1    Chung, K.Y.2    Timoney, J.P.3
  • 2
    • 0032530342 scopus 로고    scopus 로고
    • Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    • Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
    • (1998) Blood , vol.92 , pp. 1927-1932
    • Coiffier, B.1    Haioun, C.2    Ketterer, N.3
  • 3
    • 0242468884 scopus 로고    scopus 로고
    • A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
    • suppl 16
    • Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003 (suppl 16)
    • (2003) Semin Oncol , vol.30 , pp. 117-124
    • Cobleigh, M.A.1    Langmuir, V.K.2    Sledge, G.W.3
  • 4
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 5
    • 20644432867 scopus 로고    scopus 로고
    • Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Hainsworth J, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 3502-3508
    • Hurwitz, H.1    Fehrenbacher, L.2    Hainsworth, J.3
  • 6
    • 33144475980 scopus 로고    scopus 로고
    • E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer
    • Presented at the, Orlando, FL, May 13-17
    • Miller KD, Wang M, Gralow J, et al: E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
    • (2005) 41st Annual Meeting of the American Society of Clinical Oncology
    • Miller, K.D.1    Wang, M.2    Gralow, J.3
  • 7
    • 1542289007 scopus 로고    scopus 로고
    • A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
    • Cole BF, Gelber RD, Gelber S, et al: A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 14:111-124, 2004
    • (2004) J Biopharm Stat , vol.14 , pp. 111-124
    • Cole, B.F.1    Gelber, R.D.2    Gelber, S.3
  • 8
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 9
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry M, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2549, 2006
    • (2006) N Engl J Med , vol.355 , pp. 2542-2549
    • Sandler, A.1    Gray, R.2    Perry, M.3
  • 10
    • 34547173930 scopus 로고    scopus 로고
    • Berenson A: A cancer drug shows promise, at a price that many can't pay
    • Feb 15
    • Berenson A: A cancer drug shows promise, at a price that many can't pay. New York Times, Feb 15, 2006
    • (2006) New York Times
  • 11
    • 30944446883 scopus 로고    scopus 로고
    • Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    • Jain R, Duda D, Clark J, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
    • (2006) Nat Clin Pract Oncol , vol.3 , pp. 24-40
    • Jain, R.1    Duda, D.2    Clark, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.